Why These Two Gene-Editing Stocks Just Diverged - Investor's Business Daily

1. Why These Two Gene-Editing Stocks Just Diverged  Investor's Business Daily
2. CRISPR gene-editing works to reduce high cholesterol in a new study  NPR
3. Harmful cholesterol levels cut in half with one-time gene editing drug in early trial  NBC News
4. Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely Lower Cholesterol and Triglycerides  Cleveland Clinic Newsroom
5. CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering  Yahoo Finance

from Top stories - Google News https://ift.tt/uiQem3k